Man Group
TVRD

Man Group’s Tvardi Therapeutics TVRD Stock Holding History

Man Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Hold
0
– – – 1659
2022
Q1 		– Sell
-303
Closed -$133K – 2410
2021
Q4 		$133K Buy
+303
New +$152K ﹤0.01% 1852
2018
Q4 		– Sell
-383
Closed -$330K – 2151
2018
Q3 		$330K Buy
+383
New +$277K ﹤0.01% 1928

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's TVRD Position: Q2 2022 in Review

Man Group held its Tvardi Therapeutics (TVRD) position steady in Q2 2022 at 0 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Man Group first reported a position in TVRD in Q3 2018 and has held it in 2 quarters since. The position peaked at $330K in Q3 2018. 178 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

  • Man Group held 0 shares of Tvardi Therapeutics worth $378K as of Q2 2022.
  • Man Group left its Tvardi Therapeutics share count unchanged in Q2 2022.
  • Tvardi Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2022, its #1659 holding.
  • Man Group first reported a position in Tvardi Therapeutics in Q3 2018 and has held it in 2 quarters since.
  • Man Group's Tvardi Therapeutics position peaked at $330K in Q3 2018.
  • 178 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.